Analyst Expectations for aTyr Pharma's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on aTyr Pharma (NASDAQ:LIFE) stock, with 3 being bullish, 1 somewhat bullish, and none bearish. The company has an average price target of $31.25, which has increased by 140.38% over the past month.
September 21, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts are bullish on aTyr Pharma, with an average price target of $31.25, indicating potential upside.
The bullish sentiment from analysts, along with the significant increase in the average price target over the past month, suggests potential upside for aTyr Pharma's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100